Medicare's open wallet comes with a ledger: build the paper trail before volume
Payment at the full fee schedule rate is a win for Lucid, but the same week's $127m fraud plea shows the scrutiny every new reimbursement stream will face. Evidence discipline is a pricing asset.
Two Medicare stories, one lesson
Last week's material offered two Medicare headlines that look unrelated. Lucid Diagnostics said Medicare is paying EsoGuard claims at $1,938.01 per test, the full fee schedule rate, and reported record October volume. Separately, the US Justice Department said Daniel Lee, a Queens adult day care director, pleaded guilty to conspiracy to commit health care fraud and money laundering in a $127m scheme involving unnecessary prescription drugs and adult day care services never delivered.
Nothing connects the two, and I am not suggesting otherwise. But they describe the same system from opposite sides. Medicare is willing to pay a premium price for a new product, and it is also a payer that is repeatedly defrauded and knows it. Any company that builds a revenue line on Medicare has to expect to be judged in that context.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Adjusted EBITDA is the headline number. This earnings season shows why the bridge matters more
Harrow, Liquidia and CorMedix each reported strong operating metrics beside very different GAAP and guidance pictures. Leaders should judge the bridge between those numbers, not the number on top.
The real divide this earnings season is runway: who sets the timeline, and who is set by it
Revenue growth, settlements and trial milestones all matter, but the Q3 filings show the balance sheet decides who can act on them at a time of their own choosing.
Litigation is a launch cost, and earnings season is finally pricing it that way
Liquidia's $389.7 million settlement charge and Harrow's guidance reset show that the cost of defending a franchise belongs in the business case, not in a footnote below adjusted EBITDA.